News
Archive
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters
Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study
Finally, Graphene electronic devices available for all
DARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations
Back To News![Resolve Therapeutics](https://www.newscienceventures.com/wp-content/uploads/2022/11/Resolve-logo-resolve-180.png)
October 17, 2017
Resolve Therapeutics
Focused on the development of a biologic therapy for Lupus and Sjögren’s Syndrome.